Mortality from colorectal cancer is reduced through screening and early detection; moreover,
removal of neoplastic lesions can reduce cancer incidence. While understanding of the risk …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …

Colorectal cancer (CRC) exhibits differences in incidence, pathogenesis, molecular
pathways and outcome depending on the location of the tumor. This review focuses on the …

Background and Aims Colorectal cancer (CRC) is a heterogeneous disease that can
develop via several pathways. Different CRC subtypes, identified based on tumor markers …

OBJECTIVES: Evidence suggests a possible role ofFusobacterium nucleatumin colorectal
carcinogenesis, especially in right-sided proximal colorectum. Considering a change in …

Evidence indicates that diet, nutrition, lifestyle, the environment, the microbiome, and other
exogenous factors have pathogenic roles and also influence the genome, epigenome …

BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through
its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter …

Background & Aims Categorization of colon cancers into distinct subtypes using a
combination of pathway-based biomarkers could provide insight into stage-independent …